Abstract A 2012 committee opinion from the American College of Obstetricians and Gynecologists highlights the considerable increase in opioid addiction in recent years, yet little is known about clinical correlates of prescribed opioids among pregnant women. This study examines clinical and demographic factors associated with the use of opioid analgesics in pregnancy. Data were derived from a prospective cohort study of pregnant women. Participants were administered the Composite International Diagnostic Interview to identify depressive and anxiety disorders and data on medication use were gathered at three assessment points and classified according to the Anatomical Therapeutic Chemical Code (ATC) classification system ATC group N02A. Participants included 2,748 English or Spanish speaking pregnant women. Six percent (n = 165) of women used opioid analgesics at any point in pregnancy. More pregnant women using opioids met diagnostic criteria for major depressive disorder (16 vs. 8 % for non users), generalized anxiety disorder (18 vs. 9 % for non users), post-traumatic stress disorder (11 vs. 4 % for non users) and panic disorder (6 vs. 4 % for non users). Women who reported opioid use were also significantly more likely than non users to report using illicit drugs and almost three times as likely to report smoking cigarettes in the second or third trimester of pregnancy (4 and 23 %, respectively) as compared to non-opioid users (0.5 and 8 %). The use of opioids in pregnancy was associated with higher levels of psychiatric comorbidity and use of other substances as compared to non-opioid users.
Introduction
The non-medical use of prescription opioids has increased dramatically over the past two decades to ''epidemic'' proportions with an estimated 10 million individuals [1] [2] [3] [4] [5] [6] . Moreover, prescription opioids have been shown to surpass illicit drugs as the most commonly initiated drugs within the past year [7] . Emergency department visits, admissions to substance abuse treatment facilities, and overdose deaths associated with non-medical use of prescription opioids have accompanied the growth in prescription use [7] [8] [9] . Specific to pregnant women in the United States, between 6 and 26 % of women use a prescription opioid in pregnancy, with variation by state [10] , although only a handful of studies have examined the topic [10] [11] [12] . Opioid concentrations in maternal blood, even in therapeutic doses, have been linked to fetal withdrawal and overdose, and risk for perinatal stroke [13] [14] [15] [16] . The impact of opiate use in pregnancy on infant outcome has been shown to last well into early childhood [17] [18] [19] .
The co-occurrence of psychiatric disorders and opioid use and misuse in non-pregnant women has been well documented. Individual characteristics and psychosocial factors strongly predict prescriptions for opioid use and misuse [20] [21] [22] . However, individuals with comorbid psychiatric conditions associated with opioid use and misuse are often excluded from studies of opioid use in pregnancy. The majority of studies to date have examined opioid use among pregnant women seeking treatment for substance abuse or diagnosed with a substance use disorder. To our knowledge, there has only been one study to examine the psychiatric correlates of opioid use in a general cohort of pregnant, non-substance abusing women [23] . The co-morbidity of psychiatric diagnoses and opioid use in pregnant women is necessary for clinicians and maternal and child health professionals to understand in order to better design education, screening and intervention programs that may necessitate programming across multiple domains. Specific to the safety of opioids in pregnancy, researchers should aim to disentangle the effects of opioid use and psychiatric diagnoses in pregnancy that may differentially impact maternal and child health outcomes. Defining how commonly opioids are used in pregnancy, which opioids are used, and other co-occurring psychiatric disorders associated with opioid use in pregnancy are important in operationalizing research priorities in the field.
This study adds to the extant literature through an exploration of the correlates of opioid use obtained prospectively across pregnancy in a cohort of pregnant women not specifically recruited for either a substance use diagnosis or treatment. We examine rates of opioid use at any point in pregnancy and evaluate diagnostic and demographic determinants of opioid use. We hypothesized that pregnant women using prescription opioids would be more likely to meet clinical criteria for a psychiatric diagnosis and be more likely to use other licit and illicit substances in pregnancy as compared to their non-opioid using counterparts.
Materials and Methods

Study Design
The methods of this study are presented in full elsewhere [24] but are described briefly herein. Data were derived from a large prospective cohort study of pregnant women who were enrolled between March of 2005 and May of 2009 in a Northeastern city in the United States with the primary aims of examining whether a diagnosis of major depressive disorder and/or use of a psychotropic medication were associated with adverse birth outcomes. Women were recruited from 137 obstetrical practices and hospitalbased clinics throughout Connecticut and Western Massachusetts via informational letters and other printed methods of advertising. For this study, women were interviewed inperson prior to 16 completed weeks gestation and reinterviewed by phone at 28 (±2) weeks gestation and again at 8 (±4) weeks postpartum.
Inclusion/Exclusion Criteria
Women were eligible to participate if they were at least 18 years of age, had not yet completed their 16th week of pregnancy and were willing to provide written informed consent. Women were ineligible if they: (1) had a known multi-fetal pregnancy, (2) suffered from insulin-dependent diabetes, (3) did not speak English or Spanish, (4) did not have access to a telephone, (5) had plans to relocate or (6) intended to terminate their pregnancy at screening. Figure 1 illustrates study recruitment. An initial 9,525 women volunteered to be screened, of whom 1,905 (20 %) met entrance criteria and screened positive for a depressive episode within the last 5 years and/or experienced trauma with flashbacks and/or were undergoing antidepressant treatment. An additional group of 4,533 (48 %) met entrance criteria and screened negative for these clinical characteristics. We invited all women who screened positive and randomly selected 1,612 (36 %) who screened negative to participate. Of these 3,517 potential participants, we interviewed 2,793. All women completed written informed consent and the study received IRB approval from a university and affiliated hospitals. Women were included in the analytic cohort if they delivered a singleton, miscarried, or underwent a voluntary termination and provided complete data for opioid use (n = 2,748). Most missing data were due to women being out of contact for the second interview. Opioid users were no more likely than non-opioid users to fall out of contact (p = .9318).
Study Recruitment
Exposure and Outcome Measures
At each assessment point information about psychiatric symptoms was obtained through administration of the depressive disorder, generalized anxiety disorder and panic disorder modules of the WMH-CIDI [25] (see Yonkers 2012 [24] for complete list of instrumentation). A probable diagnosis of post-traumatic stress disorder was determined through administration of the Post-Traumatic Stress Disorder Symptom Scale [26] .
Women who reported medication use were asked to provide the name of the medication and ideally, to show medication bottles to the interviewer. If the bottle was unavailable, respondents were asked to view pictures of various types of pills and capsules to aid their recall. Participants were asked again at subsequent interviews about the use of recent and current medication, amount and dates of cigarette smoking, alcohol use, and illicit drug use. Illicit drugs included marijuana, cocaine, heroin, LSD, PCP, methamphetamines, or any other illegal drug endorsed by women. The Anatomical Therapeutic Chemical Code (ATC) classification system was used to classify opioid analgesics in ATC group N02A and N07BC (methadone, and buprenorphine) [23, 27] . These drugs were included because they are both used for treating pain in some patients and also for opioid maintenance therapy. Utilization of opioids in pregnancy was captured by month according to four categories: [1] no use; [2] used 1-7 days in a month; [3] used 8-14 days a month; [4] used 14 or more days (but not every day) and [5] used daily. Each participant endorsing opioid use was classified as using opioids at any point in pregnancy. Reasons for all prescription and nonprescription medication use were obtained by trained interviewers at all interviews and classified according to ICD-10 codes. A physician (KAY) with a specialization in addiction medicine, psychiatry, and obstetrics, coded all opioid use as either ''due to a medical condition that may be treated with an opioid'' or a ''medical condition not commonly treated with an opioid'' as a proxy for nonmedical recreational use of opioids. In addition, we examined non-medical opioid use defined as women who took opioids during three separate months of pregnancy versus women who took opioids in short intervals. A full list of medical conditions endorsed by participants and coded as likely to be treated with a prescription opioid is included in supplemental Table 1 . Trained medical record reviewers who were masked to a woman's psychiatric and opioid status obtained data on pregnancy outcomes.
Interviewers and Quality Control
Interviewer training on the CIDI and other instruments included a minimum of 4 days of didactics, review of training tapes that illustrated interview techniques and administration of the interview, completion of at least six practice interviews and a minimum of four supervised interviews before becoming eligible to conduct independent interviews. (see Yonkers et al. [24] for full description of methods) We audiotaped interviews with permission of participants and randomly selected a subset of tapes for quality control assessment.
Statistical Procedures
Opioid analgesic use versus no use of opiods at any time during pregnancy was the outcome variable of interest. Clinical predictors included psychiatric diagnosis (structured as any Axis 1 disorder and including major depressive disorder, post-traumatic stress disorder, generalized anxiety and panic disorders), SSRI use, any amount of substance use (smoking, illicit drugs, alcohol) during pregnancy and current or lifetime history of any medical condition likely to be treated with prescription opioids (list provided in supplementary material and determined in consultation with psychiatrist (KAY)). Alcohol use was coded as a binary variable (Y/N) defined as ''heavy alcohol use'' and included having four or more drinks per week or three or more drinks in one sitting. To examine the association between opioid use in pregnancy and clinical and demographic characteristics, we fit a multivariable logistic regression model that contained variables determined a priori based on the relevant literature and included race/ethnicity, education, psychiatric disorder, SSRI use, substance use, and any medical condition likely to be treated with prescription opioids as predictors. Odds ratios and 95 % confidence intervals were estimated for this model. Table 1 presents the means and percentages of the demographic and clinical characteristics of the analytic cohort. Mean years of education was 15.28 (±2.79) and the majority of mothers self-reported as white (73.81 %). Of the 2,748 pregnant women included in our analytic cohort, 2,654 (96.58 %) were singleton live births, 75 (2.73 %) miscarriages, 12 (0.44 %) abortions, and 7 (0.25 %) still births.
Results
Six percent of women in our sample (n = 165) endorsed taking some kind of prescription opioid in pregnancy. As shown in Table 2 , acetaminophen with oxycodone was the most commonly used opioid in pregnancy (39 %), followed by acetaminophen with codeine (27.5 %) and hydrocodone with acetaminophen (10.2 %). Among the opioid users, we determined 20 % (n = 33) to have used a prescription opioid for a current or lifetime medical condition that may require treatment with opioids, whereas about eight percent (7.8 %, n = 203) of the-non opioid users also had such a condition (p \ .001). Women who used opioids in pregnancy were more likely to have a small for gestational age birth (11.5 %, n = 19) as compared to women who did not report opioid use in pregnancy (7.7 %, n = 201) (p = .02).
Associations Between Opioid Use and Demographic and Clinical Characteristics
The results of the logistic regression analysis are summarized in Table 3 . Demographic differences between opioid users and non-users did not exist when we controlled for the effects of women's clinical characteristics. However, with the exception of alcohol use and preterm birth, all of the clinical characteristics were positively associated with opioid use. The odds of opioid use during pregnancy among women reporting any Axis 1 depressive or anxiety disorder or SSRI use were nearly double the odds for women with no Axis 1 depressive or anxiety disorder or no SSRI use. Illicit drug use during the second or third trimester was significantly associated with opioid use (OR 2.88; 95 % CI 1.02-8.19; p \ .05), but illicit drug use during the first trimester was not (OR 0.95; 95 % CI 0.52-1.75; p = .87). Compared with women who did not smoke cigarettes during pregnancy, women who smoked during the first trimester (OR 1.88; 95 % CI 1.07-3.32; p \ .03) or second or third trimester (OR 2.66; 95 % CI 1.66-4.28; p \ .0001) had greater odds of using opioids during pregnancy. The estimated odds for women who reported current or lifetime history of medical conditions that were likely to be treated with prescription opioids were nearly three times the odds for women who did not report such medical conditions (OR 2.77; 95 % CI 1.81-4.22; p \ .0001).
Discussion
This study documents the considerable psychiatric comorbidity associated with prescription opioid use in a Matern Child Health J (2015) 19:548-556 551 pregnant cohort of primarily Caucasian, educated women. Current knowledge about the psychiatric comorbidity of prescription opioid use in pregnancy is scarce, with extant research based primarily on populations of opioid maintained pregnant women [28] [29] [30] , or on larger community samples and registry-based investigations which lack detailed information on psychopathology [10, 23, [31] [32] [33] or specific drug classification [34] [35] [36] [37] . Thus, the findings presented herein are unique in their examination of prescription opioid use among a pregnant population of women with well characterized information on psychiatric comorbidity.
The prevalence of prescription opioid use in our sample (6 %) agrees with the prevalence of prescription opioid use in a population of perinatal women in a large cohort of insurance beneficiaries in the third trimester of pregnancy Table 1 not in treatment for substance abuse [10] and aligns with the state-level prescription prevalence in the State in which the study occurred. Our results support findings from large population-based studies that indicate short-acting codeine and hydrocodone are the most frequently prescribed opioid analgesics in pregnancy both in Europe [23] and the United States [10, 38] . Although common in medications such as prescription cough syrups and in general found to be safe for use in pregnancy [39] , neonatal codeine withdrawal has been observed in infants of mothers not addicted to other substances [13] . Clinical implications for our findings include the importance of obtaining a detailed history of maternal medication intake in pregnancy. Pregnant women may be under the mistaken impression that because opioids are prescribed by physicians and used to treat medical conditions they are ''safer'' than other illicit drugs in pregnancy [3] . Mothers may not consider a prescribed cough medication to be a ''drug'' and thus questions which probe both prescription and illicit drugs use should be utilized. Our proposed hypothesis was supported by our data. All psychiatric and substance use variables were associated with opioid use in pregnancy, with the exception of alcohol use. Women who met criteria for a psychiatric disorder in pregnancy, women who smoked, and women who took an SSRI in pregnancy all independently, had double the odds of using opioids in pregnancy as compared to their counterparts without a diagnosis and who did not endorse licit and illicit substance use. In pregnant populations of women on opioid maintenance treatment, rates of co-occurring disorders are high, especially for depression (35-73 %) [28, 29] , however, we have little extant information on comorbidity in pregnant women not in treatment for substance abuse and non-opioid maintained women.
Women who used prescription opioids in pregnancy represent a group of women with other adverse health behaviors. For example, women who continued to use illicit substances in their second or third trimester of pregnancy, a population at high risk for poor maternal and fetal outcomes, were also almost three times as likely to use a prescription opioid. This finding suggests either [1] women using illicit substances in pregnancy may also be abusing prescription opioids in pregnancy [2] , pregnant women substance abusers are more likely to have a medical condition which requires the use of a prescription opioid, for example, methadone [3] , prescription opioid use may independently predict psychopathology; or [4] psychopathology may independently predict prescription opioid use. Although our study was a secondary data analysis and was not designed to answer these questions, findings from large epidemiological cohorts of non-pregnant women indicate non-medical use of prescription medication is a risk factor for the onset of psychopathology, is a stronger risk factor than other illicit drug use [40] , and also increases reoccurrence of alcohol and substance use disorders [41] . Additionally, studies that have found associations between depression and antidepressant use and birth outcomes [42, 43] may not have controlled for other prescription drug use, which we have found in this sample, can be close to 6 %, and thus important to consider. Our study, which may underreport opioid use, suggests that adverse birth outcomes found among women with depressive and other psychiatric symptoms may be confounded by opioid use. In addition to the limitations already noted, our results should be interpreted with consideration of the following. First, while accuracy of self-report for medications taken for chronic conditions (e.g., antihypertensive medications) has been reported to range from ''moderate to substantial'' accuracy of maternal self-report for medications taken episodically or for a short period of time (e.g., opioid analgesics) often is much lower [44] . Our reliance on selfreport data for medication use may add substantial bias to our findings as we collapsed prescription opioid use into one single category in pregnancy. Although women were asked to report use over a period of 3-4 months, we did not examine use by trimester, thus women only needed to recall use of prescription medications in small time intervals. Finally, this study was not designed to examine prescription drug misuse, and thus we can only draw preliminary conclusions regarding the appropriateness of use of opioids through our proxy variable on general medical conditions. With a larger sample recruited specifically to examine prescription opioid use in pregnancy, we may have been able to sort out subtypes of nonmedical opioid users (e.g. polysubstance users and nonmedical opioid users with health-related problems) [20, 21, 45 ], but we are unable to draw conclusions on categories of prescription opioid use given the design of our study. In general, what constitutes prescription medication misuse is still heavily debated [46, 47] .
Several guidelines on the management of opioid dependent pregnant women exist [48] [49] [50] with the most recent published by the American College of Obstetricians and Gynecologists in 2012. Critically important to these guidelines is the recommendation for obstetric providers to screen pregnant women for substance abuse as part of complete obstetric care. Based on 2007 questionnaire data from surveys with obstetrician-gynecologists in the United States, 98 % of providers asked women about prescription drugs, but far fewer asked about illegal drugs or whether prescription medication was taken in a medically inappropriate manner (51 %) [51] . ACOG recommends all pregnant women should be routinely asked about their use of alcohol and drugs, including prescription opioids and other medications used for nonmedical reasons. The guidelines also suggest monitoring infants of women who use opioids during pregnancy for neonatal abstinence syndrome, which is characterized by hyperactivity of the central and autonomic nervous system [52] . Early identification of women who abuse and more generally use prescription opioids in pregnancy may benefit maternal and infant outcomes given our findings on the link between maternal psychopathology, illicit substance use and prescription opioid use. Future research should examine the relationship between maternal psychopathology, patterns and subtypes of prescription opioid use and misuse, and course of use in the perinatal period.
